Mesoblast Strengthens Pipeline with CAR Technology Acquisition
Mesoblast Limited (ASX: MSB) has secured exclusive global rights to a patented chimeric antigen receptor (CAR) platform, enhancing its capabilities in developing advanced mesenchymal stromal cell (MSC) therapies. The integration of CAR technology is expected to improve the precision, targeting ability, and therapeutic potency of its cell-based treatments by enhancing their ability to localize to inflamed tissues and modulate immune responses more effectively.
This advancement builds on Mesoblast’s existing MSC platform, including its FDA-approved therapy, and is aimed at addressing inflammatory and autoimmune conditions such as ulcerative colitis, Crohn’s disease, and lupus nephritis. The technology, originally developed through leading research institutions, enables engineered MSCs to achieve superior tissue-specific targeting and immunomodulation.
The acquisition aligns with Mesoblast’s strategic focus on expanding its therapeutic applications and improving treatment efficacy, reinforcing its leadership position in regenerative medicine and next-generation cellular therapies.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Mesoblast Strengthens Pipeline with CAR Technology Acquisition
Mesoblast Limited (ASX: MSB) has secured exclusive global rights to a patented chimeric antigen receptor (CAR) platform, enhancing its capabilities in developing advanced mesenchymal stromal cell (MSC) therapies. The integration of CAR technology is expected to improve the precision, targeting ability, and therapeutic potency of its cell-based treatments by enhancing their ability to localize to inflamed tissues and modulate immune responses more effectively.
This advancement builds on Mesoblast’s existing MSC platform, including its FDA-approved therapy, and is aimed at addressing inflammatory and autoimmune conditions such as ulcerative colitis, Crohn’s disease, and lupus nephritis. The technology, originally developed through leading research institutions, enables engineered MSCs to achieve superior tissue-specific targeting and immunomodulation.
The acquisition aligns with Mesoblast’s strategic focus on expanding its therapeutic applications and improving treatment efficacy, reinforcing its leadership position in regenerative medicine and next-generation cellular therapies.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au